AU2018251616B2 - Methods for the treatment of inflammation and inflammatory conditions - Google Patents

Methods for the treatment of inflammation and inflammatory conditions Download PDF

Info

Publication number
AU2018251616B2
AU2018251616B2 AU2018251616A AU2018251616A AU2018251616B2 AU 2018251616 B2 AU2018251616 B2 AU 2018251616B2 AU 2018251616 A AU2018251616 A AU 2018251616A AU 2018251616 A AU2018251616 A AU 2018251616A AU 2018251616 B2 AU2018251616 B2 AU 2018251616B2
Authority
AU
Australia
Prior art keywords
lactobacillus
strains
subject
cultured
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018251616A
Other languages
English (en)
Other versions
AU2018251616A1 (en
Inventor
Wayne FINLAYSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servatus Ltd
Original Assignee
Servatus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901320A external-priority patent/AU2017901320A0/en
Application filed by Servatus Ltd filed Critical Servatus Ltd
Publication of AU2018251616A1 publication Critical patent/AU2018251616A1/en
Application granted granted Critical
Publication of AU2018251616B2 publication Critical patent/AU2018251616B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018251616A 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions Active AU2018251616B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017901320 2017-04-11
AU2017901320A AU2017901320A0 (en) 2017-04-11 Methods for the treatment of inflammation and inflammatory conditions
AU2017902271A AU2017902271A0 (en) 2017-06-15 Methods for the treatment of inflammation and inflammatory conditions
AU2017902271 2017-06-15
PCT/AU2018/050326 WO2018187838A1 (en) 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions

Publications (2)

Publication Number Publication Date
AU2018251616A1 AU2018251616A1 (en) 2019-10-17
AU2018251616B2 true AU2018251616B2 (en) 2025-04-03

Family

ID=63792160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018251616A Active AU2018251616B2 (en) 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions

Country Status (8)

Country Link
US (2) US20200376047A1 (enExample)
EP (1) EP3609515A4 (enExample)
JP (1) JP7494110B2 (enExample)
CN (1) CN110753553A (enExample)
AU (1) AU2018251616B2 (enExample)
CA (1) CA3059453A1 (enExample)
SG (1) SG11201908857QA (enExample)
WO (1) WO2018187838A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109172613B (zh) * 2018-08-14 2022-04-22 景岳生物科技(中国)有限公司 含乳杆菌死菌培养物的皮肤外用组合物及其于促进伤口愈合及降低疤痕产生的用途
EP3863656A4 (en) * 2018-10-10 2022-06-29 Servatus Ltd Methods of treatment of inflammatory conditions and associated infections
GB201905386D0 (en) * 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
EP3815700A1 (en) * 2019-10-30 2021-05-05 Biomillenia SAS Medical compositions and their use in treating inflammatory bowel disease
US12329181B2 (en) * 2020-02-28 2025-06-17 Terragen Holdings Limited Microbial feed supplement composition and method
CN115551524A (zh) * 2020-03-31 2022-12-30 赛瓦图斯有限公司 用于炎性肠病的组合疗法
CN111733110B (zh) * 2020-07-17 2021-10-22 佛山市朗芯生物科技有限公司 副干酪乳杆菌及其在制备治疗溃疡性结肠炎药物中的应用
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
WO2022115907A1 (en) * 2020-12-01 2022-06-09 Servatus Ltd Methods for improving sleep quality
AU2021397808A1 (en) * 2020-12-09 2023-07-06 Servatus Ltd Combination therapy for inflammatory disorders of the joints
CN112522160B (zh) * 2020-12-24 2022-05-10 广东省科学院微生物研究所(广东省微生物分析检测中心) 一株具有抗病毒能力的发酵乳杆菌pv22及其应用
KR102268128B1 (ko) * 2021-02-09 2021-06-22 주식회사 락토메이슨 모유 유래 신규한 락토바실러스 루테리 lm1071 균주, 및 상기 균주 또는 이의 배양물을 포함하는 월경전 증후군 완화용 조성물
CN114456967B (zh) * 2021-10-14 2022-10-04 命之源(杭州)生物科技有限公司 一种酵母、乳酸菌联合菌、培育方法及其应用
WO2023097375A1 (en) * 2021-12-02 2023-06-08 Servatus Ltd Methods for the treatment of constipation
KR102879081B1 (ko) * 2023-03-28 2025-11-05 제이에스바이오컴퍼니 주식회사 락토바실러스 파카라제이 및 락토바실러스 부크네리를 포함하는 유산균 배양액 제조 방법 및 이를 이용한 피부 개선 기능성 원료 제조 방법
WO2025054048A1 (en) * 2023-09-08 2025-03-13 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating lipid and cholesterol metabolism associated diseases, disorders, and conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028402A1 (en) * 2000-10-06 2002-04-11 Société des Produits Nestlé S.A. Use of probiotic lactic acid bacteria for balancing the skin's immune system
WO2004069178A2 (en) * 2003-01-30 2004-08-19 Biogaia Ab Anti-inflammatory activity from lactic acid bacteria
WO2008064893A1 (en) * 2006-12-01 2008-06-05 Organobalance Gmbh Compositions, kits and uses for protecting the skin against pathogenic microorganisms
WO2014172758A1 (en) * 2013-04-23 2014-10-30 International Marketing Partnerships Pty Ltd Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175305A1 (en) * 2002-01-08 2003-09-18 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
AU2013201442B2 (en) * 2005-09-28 2014-10-30 Nordic Rebalance A/S Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors
KR100858840B1 (ko) * 2007-03-05 2008-09-17 (주)네오팜 신규 유산균 균주 및 이를 포함하는 유산균 제제
EP2205259B1 (en) * 2007-10-02 2014-12-10 Institut National de la Recherche Scientifique Mpm (malleable protein matrix) for use in the treatment of arthritis, obesity, insulin resistance, type 2 diabetes, autoimmune disease, hypertension, and hyperlipidemia
WO2012039615A2 (en) * 2010-09-21 2012-03-29 Winclove Bio Industries B.V. Commensal rat ileum bacterium (crib)
US20140147427A1 (en) * 2011-06-08 2014-05-29 Organobalance Gmbh Spray-Dried Lactobacillus Stems/Cells and the Use of Same Against Helicobacter Pylori
CA2854362C (en) 2011-11-04 2018-10-16 International Marketing Partnerships Pty Ltd Microbial inoculants and fertilizer compositions comprising the same
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AR101538A1 (es) * 2014-09-25 2016-12-28 Terragen Holdings Ltd Cepas bacterianas que tienen actividad antimicrobiana y composiciones de biocontrol que las comprenden

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028402A1 (en) * 2000-10-06 2002-04-11 Société des Produits Nestlé S.A. Use of probiotic lactic acid bacteria for balancing the skin's immune system
WO2004069178A2 (en) * 2003-01-30 2004-08-19 Biogaia Ab Anti-inflammatory activity from lactic acid bacteria
WO2008064893A1 (en) * 2006-12-01 2008-06-05 Organobalance Gmbh Compositions, kits and uses for protecting the skin against pathogenic microorganisms
WO2014172758A1 (en) * 2013-04-23 2014-10-30 International Marketing Partnerships Pty Ltd Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERMUDEZ-BRITO M. ET AL.: PLOS ONE, vol. 7, no. 8, 14 August 2012 (2012-08-14), pages 1 - 11, XP055540504, Retrieved from the Internet [retrieved on 20180706] *
FULGIONE A. ET AL.: PLOS ONE, vol. 11, no. 7, 6 July 2016 (2016-07-06), pages 1 - 16, XP055540496, Retrieved from the Internet [retrieved on 20180706] *

Also Published As

Publication number Publication date
EP3609515A1 (en) 2020-02-19
US20200376047A1 (en) 2020-12-03
US20250032563A1 (en) 2025-01-30
WO2018187838A1 (en) 2018-10-18
EP3609515A4 (en) 2020-11-04
AU2018251616A1 (en) 2019-10-17
CN110753553A (zh) 2020-02-04
JP7494110B2 (ja) 2024-06-03
CA3059453A1 (en) 2018-10-18
SG11201908857QA (en) 2019-10-30
JP2020516684A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
US20250032563A1 (en) Methods for the treatment of inflammation and inflammatory conditions
US20210338749A1 (en) Methods of treatment of inflammatory conditions and associated infections
JP6429131B2 (ja) 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用
CN106255504A (zh) 含有槲皮素糖苷的肌肉萎缩抑制剂
US10723751B2 (en) Compositions and methods for treating infectious disease
JP7379152B2 (ja) 筋線維化抑制用組成物
US20230149481A1 (en) Combination therapy for inflammatory bowel disease
JP7654014B2 (ja) 細菌株を含む組成物、ならびに眼の疾患および病変の処置のための同組成物の使用
US20240033309A1 (en) Combination therapy for inflammatory disorders of the joints
JP7626713B2 (ja) コンドロイチン硫酸合成促進用組成物
US11020440B2 (en) Probiotic for the treatment of psoriasis
TWI620566B (zh) 三萜混合物用以治療多發性硬化的用途
Coetzer OTC treatment of the side effects of antibiotics: OTC management

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)